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Aims Experimental data point towards a favourable effect of low serum concentrations of complement mannose-binding
lectin (MBL) on myocardial ischaemia/reperfusion (I/R) injury. As comparable data on the role of MBL in human I/R
injury is lacking, we investigated the influence of low serum MBL concentrations on mortality of patients with acute
ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods
and results
Mannose-binding lectin was determined in 890 acute STEMI patients that were prospectively recruited in the APEX-
AMI trial. This trial had a primary endpoint of death through Day 30 and secondary endpoints of death through Day
90 and the composite of death, cardiogenic shock, or congestive heart failure (CHF) through Days 30 and 90.
Samples were taken immediately before PCI and the analysis of MBL limited to patients having received placebo.
Patients with serum MBL levels of or below 100 ng/mL were considered to be functionally deficient. Of the 890
patients, 127 had functional MBL deficiency (14.3%). Characteristics of patients with MBL deficiency and those
with MBL levels .100 ng/mL did not differ. In patients with MBL deficiency, there was 1 death (0.79%) compared
with 42 deaths (5.51%) in patients with MBL levels .100 ng/mL (P ¼ 0.0233) representing an absolute and relative
lower mortality in MBL deficient patients of 4.7 and 85%, respectively. Functional MBL deficiency, however, was not
associated with decreased risk of the combined endpoints of death and shock or death, shock, and CHF, respectively.
Conclusion Functional deficiency of complement MBL is associated with reduced mortality in patients with STEMI undergoing
PCI. This unique finding suggests that a component of the innate immune system affects mortality in STEMI patients
undergoing primary PCI.
Trial Registration: clinicaltrials.gov, Identifier: NCT00091637.
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Introduction
Myocardial infarction is a leading cause of morbidity and mortality
worldwide. As infarct size is a major determinant of mortality in
myocardial infarction, limitation of infarct size has been an impor-
tant objective of strategies to improve outcomes.1 Currently, the
most effective way to limit infarct size is to reperfuse ischaemic
myocardium as soon as possible, e.g. by the use of percutaneous
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transluminal coronary intervention (PCI). Although early
reperfusion is undoubtedly beneficial, the process of reperfusion
itself results in inflammation and tissue damage named myocardial
ischaemia/reperfusion (I/R) injury.2– 5 Therefore, a number of anti-
inflammatory treatment strategies accompanying myocardial
reperfusion have been investigated to reduce myocardial I/R
injury.6– 8 However, these strategies have had limited success poss-
ibly, because the mechanisms involved in myocardial I/R are still
not fully understood.
Mannose-binding lectin (MBL) is a pattern recognition molecule
that is part of the complement cascade and the innate immune
system. The name of the molecule is derived from its capacity to
bind to terminal mannose groups that are found on a variety of
pathogens as well as on apoptotic cells. Binding of MBL leads to
the activation of complement via the so-called MBL pathway. Inter-
estingly, due to genetic polymorphisms in the promoter region and
three variant structural alleles of MBL up to 25% of the normal
population have reduced serum concentrations of MBL and can
be classified as being functionally deficient.9
The consequences of low levels of serum MBL in adults, i.e.
functional MBL deficiency, are only partially understood.
Whereas low levels of MBL correlated with recurrent infections
in children,10– 12 the role of the MBL pathway in adults is less
clear. The majority of individuals in the general population with
low MBL levels do not suffer from recurrent infections nor seem
high levels of MBL to be a problem.13–16 However, in the cardio-
vascular system, there seems to be a fine balance as to when low
MBL levels may be harmful17– 19 or beneficial20,21 suggesting a role
of MBL that is strongly dependent on the type of inflammation. In
myocardial I/R injury22,23 as well as in other settings of I/R
injury,24–27 experimental data point towards a favourable effect
of low serum MBL. As comparable data on the role of MBL in
human I/R injury is lacking, the aim of the present study was to
investigate the correlation of low serum MBL concentrations
with mortality of patients with acute ST-elevation myocardial
infarction (STEMI) undergoing primary PCI.
Methods
Study objectives
The study objective was to investigate the correlation of serum MBL
concentrations with 90-day mortality alone or the combined endpoints
of mortality and shock or mortality, shock, and CHF in patients with
acute STEMI undergoing primary PCI.
In a sub-analysis, we investigated whether functional MBL deficiency
was associated with reduced serum creatine kinase (CK) or CK-MB
levels as well as with reduced markers of complement activation
after 24 h after PCI.
Patients
All patients were prospectively recruited in the context of the Assess-
ment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI)
trial.28 In this trial, 5745 patients with STEMI from 17 countries and
296 sites were enrolled between 13 July 2004 and 11 May 2006.7
Eligibility for enrolment required patients to be at least 18 years of
age and to present within 6 h of symptoms that were deemed
ischaemic and that had persisted for at least 20 min. Patients were
expected to undergo primary PCI and were required to have high-risk
electrocardiographic characteristics: these included at least 2-mm
ST-elevation in two anterior lateral leads or at least 2-mm ST-elevation
in two inferior leads coupled with ST-depression in two contiguous
anterior leads for a total of 8 mm or more or a new left-bundle
branch block with at least 1-mm concordant ST-elevation.
The outcome of patients having been treated with the complement
C5 inhibitor pexelizumab did not differ from patients having received
placebo.7 However, as the treatment might have affected the analyses
of complement MBL, in this study, we limited our analyses to patients
receiving placebo. Thus, the present study included all patients from
the APEX-AMI trial that had received placebo and in which serum
taken at study inclusion was available (see below).
Patients were excluded if they had isolated inferior MI, were preg-
nant or breastfeeding, had known or suspected complement deficiency
or active serious infection, or had other serious medical conditions
likely to alter their recovery. Prior fibrinolytic therapy for treatment
of the qualifying event was also a basis for exclusion. No upper age
limit was set. The institutional review board of each participating hos-
pital approved the protocol, and patients were required to provide
written informed consent.
Definition of endpoints
The primary objective of the APEX-AMI trial was to determine
whether pexelizumab reduced all-cause mortality through Day 30.
Secondary objectives included the evaluation of pexelizumab’s effect
on death as well as the composite incidence of death, cardiogenic
shock, or congestive heart failure (CHF) through Days 30 and 90. Ter-
tiary objectives included stroke and recurrent MI at Day 90; sepsis
through hospital discharge or Day 14, whichever occurred earlier;
shock at Day 30; and 90-day composites of cardiogenic shock or
CHF, death or cardiogenic shock, and death or CHF. Causes of
death were recorded according to a standardized dictionary (Medra).
Congestive heart failure and cardiogenic shock were centrally adju-
dicated by a clinical events committee blinded to treatment assign-
ment.21 Congestive heart failure included new or worsening CHF
occurring during the index hospitalization or rehospitalization for
CHF as previously defined.7
Cardiogenic shock was defined as hypotension of less than
90 mmHg systolic blood pressure lasting for at least 1 h, not respon-
sive to fluid resuscitation and/or heart rate correction, believed to
be secondary to cardiac dysfunction, and associated with at least
one of the following signs of hypoperfusion: cool, clammy skin, oliguria,
altered sensorium, cardiac index less than or equal to 2.2 L/min/m2.
Blood sampling and storage of sera
Blood markers were obtained in the context of the sub-study ‘Inflam-
matory and other biomarkers’ in preselected centres located predomi-
nately in the USA and Canada. Consecutive patients were recruited in
these centres looking to a total of 2000 patients studied at baseline
with the first 1000 studied at baseline and 24 h. The recruitment
was stopped as the main trail was prematurely discontinued. A total
of 890 consecutive placebo patients had serum collected for MBL
determination at study inclusion and of 187 at baseline and 24 h.
The tubes were left standing for 30–45 min for complete clot for-
mation, and then centrifuged at 1800 g for 15 min at room tempera-
ture. The serum was then carefully transferred into cryovials and
frozen locally to be shipped on dry ice at the Duke Cardiovascular
Research Institute (Durham, USA) were they were kept at 2808C
until transferred on dry ice to the Montreal Heart Institute (Montreal,
Quebec, Canada) for batch analysis.
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Determination of mannose-binding lectin
and other complement parameters
Measurements of MBL concentrations were all performed on the same
day as being thawed using the MBL Oligomer Elisa Kit 029 (Antibody-
shop, Grusbakken, Denmark) run on an automated Robotic Adaltis
ELISA instrument. The standard concentrations in these kits range
from 0 to 40 ng/mL providing a range of 0–4000 ng/mL at 1/100
dilution. The coefficients of variation (CV) for the intra- and inter-assay
reproducibility are 4 and 10%, respectively. Expected values in healthy
humans are between 0 and 7000 ng/mL.
There is no unique definition of functional MBL deficiency and clini-
cally relevant levels of MBL may differ in different diseases. In general,
MBL levels ,100 ng/mL are considered to be functionally deficient,
whereas there is uncertainty in the range of 100–500 ng/mL (reviewed
by Arslan et al.8). Therefore, MBL levels of or below 100 ng/mL were
chosen for the definition of functional MBL deficiency. In a sub-analysis,
patients with levels between 100 and 500 ng/mL, i.e. intermediate
levels, were analysed separately.
The levels of the anaphylatoxins C4a and C3a were measured by a
cytometric bead array (CBA) using the Human Anaphylatoxin BD kits
(Biosciences, San Diego, USA). In these kits, beads of distinct fluor-
escence intensities are coated with specific capture antibodies specific
to complement fragments. The fluorescence was analysed on an EPICS
XL cytometer (Beckman Coulter, FL, USA), and measured using BD
CBA Software, applying a four-parameter curve fit. The sensitivity of
the assays for C4a is 10.5 pg/mL, and for C3a, 4 pg/mL. Intra-assay vari-
ation coefficients are between 3 and 5% for these tests, and inter-
assays between 11 and 16%.
Soluble sC5b-9 complex was measured by the Enzyme Immunoas-
say Kit A009 (Quidel, San Diego, USA). This assay has a lower limit
of the detection of 7.9 ng/mL at three standard deviations above
the zero standard curves, and a lowest limit for quantification of
40 ng/mL. Intra- and inter-assay CV are 5 and 10%, respectively, with
the range of values expected in healthy donors being between 40
and 6000 ng/mL and below ,1000 ng/mL.
Statistics
Baseline characteristics, CK, CK-MB, and complement activation
parameters are described depending on MBL measurements
100 ng/mL and those .100 ng/mL. Discrete factors are displayed
as frequencies and continuous measurements displayed as the 25th,
50th, and 75th percentiles. In most cases, the x2 statistical comparison
of categorical variables are reported. On occasion, when there were
few cases or events the Fisher exact method is reported. For continu-
ous variables, Wilcoxon rank sum was used to test for measures of
association. The Kaplan–Meier method was used to report outcomes
of interest for patients randomized to placebo that have baseline MBL
measurements. Events, of interest, were death, death or shock and
death, shock or CHF by Day 90 post-randomization. The Log-rank
test statistic is reported for these analyses when MBL was being ana-
lysed as a dichotomous variable. Regression analyses of outcome
data based on the Cox proportional hazards models were generated
to assess MBL’s ability to predict the events stated earlier. Hazard
ratios with 95% confidence intervals and the Score test statistic and
associated P-value are reported. Mannose-binding lectin levels were
dichotomized into two and three groups, respectively, i.e. measure-
ments 100 and .100 ng/mL or measurements 100 ng/mL, those
between 100–500 ng/mL and ones .500 ng/mL.
All analyses were performed using SAS software (versions 8.2, SAS
Institute, Cary, NC, USA).
Results
Serum mannose-binding lectin and
patient characteristics mannose-binding
lectin 100 vs. >100 ng/mL
Serum baseline MBL could be determined in all 890 patients. Of
these patients, 127 had MBL levels of or below 100 ng/mL
(14.3%) including 38 patients with undetectable MBL levels (4.3%
of the study population). In order to investigate a potential acute
phase reaction, MBL levels could also be determined at 24 h in
187 of the 890 patients. In these 187 patients, MBL levels at 24 h
did not significantly differ from baseline MBL levels (median MBL
at baseline 1446.1 ng/mL vs. MBL at 24 h 1536.1 ng/mL, P ¼
0.98). This lack of increase at 24 h was independent from baseline
MBL levels.
Characteristics of patients with MBL  100 ng/mL compared
with patients with MBL . 100 ng/mL did not differ and are sum-
marized in Table 1.
Outcome of patients with
mannose-binding lectin 100
vs. >100 ng/mL
The outcome of patients with MBL  100 ng/mL compared with
patients with MBL . 100 ng/mL is shown in Table 2. In the group
of patients with MBL levels 100 ng/mL, there was 1 death
(0.79%) compared with 42 deaths (5.51%) in patients with MBL
levels .100 ng/mL (P ¼ 0.023). This corresponded to an absolute
difference in mortality of 4.7% and a relative difference of 85% in
favour of patients with low levels of MBL. The cumulative survival
rate is shown in Figure 1A. In contrast, functional MBL deficiency
was not associated with decreased risk of the combined endpoints
of death and shock or death, shock and CHF, respectively,
suggesting that low MBL levels affected mortality alone but not
shock and heart failure (Figure 1B, P ¼ 0.676).
As summarized in Table 3, most patients died of cardiovascular
causes with cardiac arrhythmias and heart failure being the most
frequent. In the cohort of patients with MBL levels .100 ng/mL,
nine patients died of unknown and non-cardiovascular causes
(1.2%) and 33 patients died due to cardiovascular events (4.3%).
In comparison, the cause of death in the one patient who died in
the cohort of patients with MBL levels ,100 ng/mL was indicated
as ’procedural and/or device related’.
Outcome of patients with
mannose-binding lectin 100 vs.
>100 ng/mL and 500 vs. >500 ng/mL
As it is unknown at which concentration MBL levels should be con-
sidered to be functionally deficient in the setting of myocardial I/R
injury, patients with MBL levels above 100 ng/mL (n ¼ 763) were
separated into two sub-groups: patients with intermediate level
of MBL, i.e. .100 and  500 ng/mL (140 of 763) and patients
with high level of MBL, i.e. .500 ng/mL (623 of 763). As demon-
strated in Table 4, patients with intermediate MBL serum levels had
a similar outcome to that observed in patients with high levels of
MBL, suggesting that the reduced mortality observed in patients
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with functional MBL deficiency was limited to patients with MBL
levels 100 ng/mL.
Association of baseline mannose-binding
lectin levels with creatine kinase, creatine
kinase-MB, and complement
activation products
As determined in a subgroup of patients, MBL deficiency was not
associated with reduced peak CK or CK-MB levels. In addition,
serum markers of complement activation could be measured in a
small subgroup of patients before and 24 h after PCI. Mannose-
binding lectin deficiency was not associated with significantly
lower C4a, C3a, or sC5b-9 levels, neither in absolute levels nor
in relative changes of levels between baseline and 24 h after PCI.
However, in the relatively small subgroup of analysed patients
with serum MBL  100 ng/mL, there was a trend towards lower
levels of complement C4a 24 h after PCI indicating reduced
complement activation via the classical and/or MBL pathway of
complement. The data are summarized in Table 5.
Discussion
Primary PCI for acute STEMI provides a useful model for the study
of myocardial I/R injury. In the present study, we observed that
functional deficiency of the complement component MBL is associ-
ated with reduced 90-day mortality in patients with acute myocar-
dial infarction undergoing early reperfusion by catheter
revascularization. The relative difference in mortality was about
85% compared with patients with sufficient serum MBL levels.
Thus, for the first time, a component of the complement
cascade and the innate immune system could be shown to corre-
late with mortality in a human I/R situation.
Interestingly, functional MBL deficiency seemed to affect mor-
tality alone but not the combined endpoint of death, shock, and
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Table 1 Selected patient characteristics dependent on baseline serum mannose-binding lectin levels
Parameter Baseline serum MBL P-value
MBL > 100 ng/mL MBL  100 ng/mL
n 763 127
Age, median (year) 60 (51, 70) 60 (53, 73) 0.52
Female (%) 21.4 23.6 0.57
Prior CABG (%) 3.9 1.6 0.30
Prior PCI (%) 11.8 11.8 1.00
Prior MI (%) 13.2 15.7 0.44
Prior CHF (%) 2.9 3.9 0.57
History of diabetes (%) 16.9 12.6 0.22
Hyperlipidaemia (%) 49.7 53.3 0.49
Hypertension (%) 52.8 54.3 0.75
History of chronic inflammatory condition (%) 2.1 0.8 0.49
History of chronic liver disease (%) 0.8 1.6 0.32
Killip class .2 (%) 3.2 0.8 0.39
High risk inferior MI (%) 42.1 44.9 0.55
Heart rate, median (b.p.m.) 75 (64, 86) 76 (63, 86) 0.46
Systolic blood pressure, median (mmHg) 133 (116, 150) 132 (114, 148) 0.87
Body mass index, median 27.6 (24.8, 31.1) 27.1 (24.4, 31.0) 0.64
Time from symptom onset to angiography (ischaemic time), h, median 2.7 (1.9, 3.8) 2.4 (1.8, 3.7) 0.22
Values in parenthesis are 25th, 75th percentiles. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MI, myocardial infarction; CHF, chronic heart
failure.
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Table 2 Clinical outcome comparing patients with baseline mannose-binding lectin 100 vs. >100 ng/mL
Parameter, rate (95%
confidence interval)
Baseline serum MBL (ng/mL) Log-rank test statistic P-value Hazard ratio
MBL > 100 MBL  100
Death (Day 90) 5.51 (3.89–7.13) 0.79 (0–2.34) 5.1428 0.023 0.14 (0.02, 1.02)
Death or shock (Day 90) 8.01 (6.08–9.93) 3.97 (0.56–7.8) 2.4367 0.119 0.49 (0.20, 1.22)
Death, shock or CHF (Day 90) 13.24 (10.83–15.64) 11.83 (6.21–17.45) 0.1749 0.676 0.89 (0.52, 1.53)
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CHF. We could also not observe differences in CK and CK-MB
levels between MBL sufficient vs. functionally deficient patients,
suggesting that MBL levels did not affect the size of infarction.
However, when analysing the causes of death, most patients died
for cardiovascular reasons with cardiac arrhythmias and heart
failure being the most frequent events. Therefore, inflammatory
I/R injury seemed to affect the severity but not the rate of
events after reperfusion. We hypothesise that low MBL mostly
reduced the rate of fatal arrhythmia in patients with severe heart
failure, whereas the degree of heart failure due to ischaemic
tissue remained unchanged.
Functional MBL deficiency is frequent and seems to be the most
frequent immunodeficiency in man. In our study, a functional MBL
deficiency defined as MBL levels 100 ng/mL could be found in
14% of the study population which is in or slightly above the
range described by previous studies.15,29–32 This observation is
in line with clinical as well as experimental reports describing
that low MBL is a risk factor for and is involved in the development
of atherosclerosis.17,20,33 It also indicates that our data are of
importance for a significant part of the general population and sup-
ports the view that I/R injury leads to significant inflammatory
tissue damage that limits the benefits achieved by the reperfusion
procedure. As a consequence, anti-inflammatory treatment strat-
egies in I/R injury should have the potential to improve the
outcome of patients undergoing reperfusion procedures signifi-
cantly. In this context, and similar to observations made in
animal studies, MBL might serve as treatment target itself with
the aim to inhibit the function of MBL in patients who are not
already genetically deficient.22
Independent of potential therapeutic consequences, our data
contribute to the understanding of the role of complement in
human myocardial I/R injury. In I/R injury, complement activation
was described during myocardial infarction almost 40 years ago34
and has led to numerous investigations on the contribution of
the complement system to I/R tissue injury. Combined data from
a number of studies suggest that following I/R, complement may
be activated through all three pathways of complement: the classi-
cal, the alternative pathway, and the lectin pathway. However, the
exact mechanisms by which the complement system is activated
after I/R are not well established (reviewed in 35,36). In line with
our data, recent experimental studies suggested that myocardial
I/R injury might lead to damaging complement activation that at
Figure 1 Relationship between serum mannose-binding lectin
(MBL) levels and survival rate (A) or the combined endpoint of
death, shock, and congestive heart failure (CHF) (B) in patients
with acute ST-elevation myocardial infarction having undergone
primary percutaneous coronary intervention. P-values were
0.023 and 0.676, respectively.
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Table 3 Cause of death comparing patients with
baseline mannose-binding lectin 100 vs. >100 ng/mL
Cause of death Baseline serum MBL (ng/
mL)
MBL > 100 MBL  100
Sudden cardiovascular death 14 1
Heart failure 6 0
Cardiac arrhythmia 5 0
Cardiac valve disorders 1 0
Coronary artery disorders 1 0
Fatal outcomes 1 0
Procedural and device related
injuries and complications
0 1
Non-sudden cardiovascular death 19 0
Heart failure 8
Cardiac arrhythmia 10
Myocardial disorders, unspecified 1
Not cardiovascular-related death 7 0
Respiratory disorders 2
Central nervous system vascular
disorder
1
Respiratory and mediastinal
neoplasms, malignant, and
unspecified
1
Reproductive neoplasms male,
malignant, and unspecified
1
Infections, pathogen class
unspecified
1
Gastrointestinal ulceration and
perforation
1
Unknown cause of death 2 0
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least in part is mediated by the MBL pathway.22,23 Our obser-
vations that MBL deficiency is associated with reduced mortality
after PCI for acute myocardial infarction support the view that
complement MBL plays an important role in myocardial I/R
injury. Interestingly, this effect could only be seen in patients
with very low MBL levels, i.e. 100 ng/mL, suggesting that there
is no continuous relation between mortality and MBL levels.
There rather seems to be a critical concentration of MBL that dis-
tinguishes between sufficient or insufficient complement activation
in the context of I/R injury. In a small subgroup of patients, we
could analyse whether functional MBL deficiency indeed was
associated with reduced levels of complement activation products
24 h after PCI. Such an association could not be found. However,
there was a trend towards lower levels of the complement split
product C4a when compared with patients with high levels of
complement MBL which is compatible with reduced complement
activation via the MBL pathway. Considering the fact that the gen-
eration of C3a and sC5b-9 seems to be independent of the MBL
level additional complement activation via the alternative
pathway seems to be likely.
Independent of the pathway of complement relevant for the
activation in I/R injury, it also remains to be determined whether
MBL is involved in other types of human I/R injury such as
intestinal or renal I/R injury as suggested by experimental
studies.24– 26
It is important to note that the study was powered to detect a
relative difference of 50% of the combined endpoint of death,
shock, or heart failure in MBL deficient patients but not for a
50% reduction of mortality alone. Thus, the large effect seen in
MBL deficient individuals may represent an overestimate of the
true effect and be a chance result. Therefore, our data needs to
be confirmed in further studies. In addition, our study is of descrip-
tive nature and therefore cannot identify a causal relationship
between functional MBL deficiency and reduced mortality in
patients with STEMI undergoing PCI. However, the results are
well in line with observations made in experimental models22,23
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Table 4 Clinical outcome comparing patients with baseline mannose-binding lectin 100 vs. >100 ng/mL but 500 vs.
>500 ng/mL
Parameter, rate (95% confidence
interval)
Baseline serum MBL (ng/mL) Log-rank test
statistic
P-value
MBL > 500 MBL > 100 and
500
MBL  100
Death (Day 90) 5.46 (3.67–7.24) 5.76 (1.88–9.63) 0.79 (0–2.34) 5.16 0.076
Hazard ratioa 1.05 (0.49, 2.27) 0.14 (0.02, 1.04)
Death or shock (Day 90) 7.54 (5.47–9.62) 10.07 (5.07–15.08) 3.97 (0.56–7.8) 3.5124 0.173
Hazard ratioa 1.35 (0.75, 2.46) 0.52 (0.21, 1.31)
Death, shock or CHF (day 90) 13.00 (10.36–15.64) 14.30 (8.50–20.10) 11.83 (6.21–17.45) 0.3744 0.83
Hazard ratioa 1.12 (0.69, 1.82) 0.91 (0.52, 1.58)
aReference cell for reporting the hazard ratios is those with MBL values .500 ng/mL.
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Table 5 Creatine kinase, creatine kinase-MB and complement activation parameters dependent on baseline serum
mannose-binding lectin levels
Parameter, median (25th, 75th percentile) Patients (n) Baseline serum MBL P-value
MBL > 100 ng/mL MBL  100 ng/mL
Peak CK 625 1700 (772, 3134) 1452 (798, 3156) 0.614
Peak CK-MB 575 156.5 (66.1, 239.2) 148 (71.0, 286.0) 0.850
24 h C3a 105 266147 (198913, 381447) 332385 (240026, 403601) 0.431
Absolute change in C3a 105 8980 (259364, 83849) 27815 (243816, 82705) 0.823
Relative (%) change in C3a 105 3.7 (222.2, 48.5) 21.1 (211.7, 33.7) 1.000
24 h C4a 108 214627 (146980, 302809) 170970 (144000, 202238) 0.140
Absolute change in C4a 108 20708 (212943, 73182) 28755 (230994, 26556) 0.088
Relative (%) change in C4a 108 11.8 (28.3, 41.1) 20.7 (230.8, 18.3) 0.087
24 h sC5b-9 96 845 (525, 1448) 736 (382, 1447) 0.489
Absolute change in sC5b-9 89 346 (21, 959) 258 (8, 1044) 0.833
Relative (%) change in sC5b-9 89 95.8 (11.1, 333.5) 101.4 (20.4, 261.0) 0.843
Concentrations of C3a, C4a are given in pg/mL and sC5b-9 in ng/mL. Creatine kinase and CK-MB are given in U/I.
M. Trendelenburg et al.1186
and in this trial an affect on mortality alone in patients with low
MBL levels was observed despite low overall mortality.
In conclusion, functional deficiency of complement MBL was
associated with reduced mortality in patients with acute STEMI
undergoing primary PCI. Thus, MBL seems to contribute to fatal
secondary inflammatory damage of the reperfused ischaemic
heart muscle and might serve as a target for treatment strategies
aiming to reduce myocardial I/R injury.
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